Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
MUC1 is associated with cellular transformation and tumorigenicity and is considered as an important tumor-associated antigen (TAA) for cancer therapy. We previously reported that anti-MUC1 monoclonal antibody C595 (MAb C595) plus docetaxel (DTX) increased efficacy of DTX alone and caused cultured h...
Main Authors: | Li Wang, Hongmin Chen, Mohammad H Pourgholami, Julia Beretov, Jingli Hao, Hongtu Chao, Alan C Perkins, John H Kearsley, Yong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3170300?pdf=render |
Similar Items
-
Molecular manipulation and structural studies of C595 monoclonal antibody and MUC1 mucin
by: Brady, Kevin
Published: (2000) -
Detection of MUC1-Expressing Ovarian Cancer by C595 Monoclonal Antibody-Conjugated SPIONs Using MR Imaging
by: Daryoush Shahbazi-Gahrouei, et al.
Published: (2013-01-01) -
The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy
by: Ashleigh Hull, et al.
Published: (2021-12-01) -
Generation of Novel Anti-MUC1 Monoclonal Antibodies with Designed Carbohydrate Specificities Using MUC1 Glycopeptide Library
by: Shoichi Naito, et al.
Published: (2017-11-01) -
Physiological and Chemical Studies on the Bioconversion of Glycyrrhizin by Aspergillus niger NRRL595
by: El-Refai, A. M. H., et al.
Published: (2012-06-01)